KCNN4 and sickle cell disease: This builds on previous evidence on the tolerability of KCa3.1 targeting: both KCNN4−/− animal models (except impaired volume control of erythrocytes and lymphocytes42,43), as well as clinical data on the structurally-related KCa3.1 blocker senicapoc in patients with sickle cell disease did not detect serious adverse effects61.